FDA Generic Versus Innovator Study Planned For JAMA

FDA is conducting a study of bioequivalence differences between generic and brand-name drugs, Office of Generic Drugs Director Douglas Sporn told the National Association of Pharmaceutical Manufacturers annual meeting in Puerto Rico Feb. 3.